FDA Clearance Tracker · P910018-S002
LIPOSORBER LA-15 SYSTEM
Last checked: Nov 20, 2026Latest source record: Apr 9, 2002 (this decision)Source: openFDAMethods & limitations
Decided
Apr 9, 2002
Approved
Time to decision
1,211 days
Received Dec 15, 1998. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P910018-S002
- Device name
- LIPOSORBER LA-15 SYSTEM
- Applicant
- Kaneka Pharma America Corp.
- Applicant location
- New York, NY
- Received
- Dec 15, 1998
- Decided
- Apr 9, 2002
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Postapproval Study Protocol
- Original approval
- P910018
Device type
- Device type
- Lipoprotein, low density, removal (MMY)
- Device class
- Class III
- Specialty
- GI, Urology & Nephrology
FDA's approval statement
As written in FDA's record.
APPROVAL FOR MODIFICATIONS TO THE PATIENT REGISTRY/POST-MARKET STUDY OF THE LIPOSORBER. LA-15 SYSTEM.
Source documents
Other decisions for Kaneka Pharma America Corp.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
No other decisions since 2015 under this exact applicant name.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.